AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis

References

• Heart Disease and Stroke Statistics – 2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation113, e85 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med.354, 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA295, 180–189 (2006).
   PubMed Web of Science ®Google Scholar
• Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am. J. Cardiol.91(Suppl.), 3A–6A (2003).
   PubMed Web of Science ®Google Scholar
• Poole JCF, Florey HW. Changes in the endothelium of the aorta and the behavior of macrophages in experimental atheroma of rabbits. J. Pathol. Bacteriol.75, 245–253 (1958).
   PubMedGoogle Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation105, 1135–1143 (2002).
   PubMed Web of Science ®Google Scholar
• Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb.13, 197–204 (1993).
   PubMed Web of Science ®Google Scholar
• Kunsch C, Luchoomun J, Grey JY et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J. Pharmacol. Exp. Ther.308, 820–829 (2004).
   PubMed Web of Science ®Google Scholar
• Iiyama K, Hajra L, Iiyama M et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ. Res.85, 199–207 (1999).
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Allen MD, McDonald TO et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. J. Clin. Invest.92, 945–951 (1993).
   PubMed Web of Science ®Google Scholar
• Cybulsky MI, Iiyama K, Li H et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest.107, 1255–1262 (2001).
   PubMed Web of Science ®Google Scholar
• Dansky HM, Barlow CB, Lominska C et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler. Thromb. Vasc. Biol.21, 1662–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Nelken N, Coughlin S, Gordon D, Wilcox J. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest.88, 1121–1217 (1991).
   PubMed Web of Science ®Google Scholar
• Yla-Herttuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl Acad. Sci. USA88, 5252–5256 (1991).
   PubMed Web of Science ®Google Scholar
• Gosling J, Slaymaker S, Gu L et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest.103, 773–778 (1999).
   PubMed Web of Science ®Google Scholar
• Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J. Clin. Invest.92, 1866–1874 (1993).
   PubMed Web of Science ®Google Scholar
• Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1 and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-α and immunoglobuolin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J. Clin. Invest.92, 1564–1571 (1993).
   PubMed Web of Science ®Google Scholar
• Ali MH, Schlidt SA, Chandel NS, Hynes KL, Schumacker PT, Gewertz BL. Endothelial permeability and IL-6 production during hypoxia: role of ROS in signal transduction. Am. J. Physiol.277(5 Pt 1), L1057–L1065 (1999).
   PubMed Web of Science ®Google Scholar
• Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res.87, 840–844 (2000).
   PubMed Web of Science ®Google Scholar
• Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol.91(Suppl.), 7A–11A (2003).
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase: role in cardiovascular biology and disease. Circ. Res.86, 494–501 (2000).
   PubMed Web of Science ®Google Scholar
• Meng CQ, Somers PK, Rachita CL et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg. Med. Chem. Lett.12, 2545–2548 (2002).
   PubMed Web of Science ®Google Scholar
• Sundell CL, Somers PK, Meng CQ et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J. Pharmacol. Exp. Ther.305, 1116–1123 (2003).
   PubMed Web of Science ®Google Scholar
• Pfuetze KD, Dujovne CA. Probucol. Curr. Atheroscler. Rep.2, 47–57 (2000).
   PubMedGoogle Scholar
• Walldius G, Erikson U, Olsson AG et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol.74, 875–883 (1994).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Cote G, Lesperance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med.337, 365–372 (1997).
   PubMed Web of Science ®Google Scholar
• Rodes J, Cote G, Lesperance J et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation97, 429–436 (1998).
   PubMed Web of Science ®Google Scholar
• Wu BJ, Kathir K, Witting PK et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J. Exp. Med.203, 1117–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Reinoehl J, Frankovich D, Machado C et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am. Heart J.131, 1184–1191 (1996).
   PubMed Web of Science ®Google Scholar
• Wasserman MA, Sundell CL, Kunsch C, Edwards D, Meng CQ, Medford RM. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am. J. Cardiol.91(3A), 34A–40A (2003).
   PubMed Web of Science ®Google Scholar
• Roberts MJD, Young IS, Trouton TG et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet336, 143–145 (1990).
   PubMed Web of Science ®Google Scholar
• Iuliano L, Pratico D, Greco C et al. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J. Am. Coll. Cardiol.37, 76–80 (2001).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, Schwartz L et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation107, 552–558 (2003).
   PubMed Web of Science ®Google Scholar
• Meng CQ, Somers PK, Rachita CL et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg. Med. Chem. Lett.12, 2545–2548 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Meredith IT, Yeung AC et al. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med.332, 488–493 (1995).
   PubMed Web of Science ®Google Scholar
• Sasahara M, Raines EW, Chait A et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol: is the extent of atherosclerosis related to resistance of LDL to oxidation? J. Clin. Invest.94, 155–164 (1994).
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Shimizu C, Maeda N et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J. Am. Coll. Cardiol.39, 610–616 (2002).
   PubMed Web of Science ®Google Scholar
• Serebruany V, Malinin A, Scott R. The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. J. Cardiovasc. Pharmacol. Ther.11(3), 191–196 (2006).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm. Res.43, 453–462 (2001).
   Google Scholar
• Serebruany VL, Malinin AI, Lowry DR et al. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin II receptor blockers in patients after acute vascular events. J. Cardiovasc. Pharmacol.43, 677–684 (2004).
   PubMed Web of Science ®Google Scholar
• Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res.85, 753–766 (1999).
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation104, 1336–1342 (2001).
   PubMed Web of Science ®Google Scholar
• Narizhneva NV, Razorenova OV, Podrez EA et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J.19, 1158–1160 (2005).
   PubMed Web of Science ®Google Scholar
• van der Zijpp YJ, Poot AA, Feijen J. ICAM-1 and VCAM-1 expression by endothelial cells grown on fibronectin-coated TCPS and PS. J. Biomed. Mater. Res. A.65, 51–59 (2003).
   PubMed Web of Science ®Google Scholar
• Gawaz M, Page S, Massberg S et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb. Haemost.88, 307–314 (2002).
   PubMed Web of Science ®Google Scholar
• Mayer K, Merfels M, Muhly-Reinholz M et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am. J. Physiol. Heart Circ. Physiol.283, H811–818 (2002).
   PubMed Web of Science ®Google Scholar
• Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Dynamics of leukocyte-platelet adhesion in whole blood. Blood78, 1730–1737 (1991).
   PubMed Web of Science ®Google Scholar
• Weyrich AS, Elstad MR, McEver RP et al. Activated platelets signal chemokine synthesis by human monocytes. J. Clin. Invest.97, 1525–1534 (1996).
   PubMed Web of Science ®Google Scholar
• Selley ML, Bartlett MR, Czeti AL, Ardlie NG. The role of (E)-4-hydroxy-2-nonenal in platelet activation by low density lipoprotein and iron. Atherosclerosis140, 105–112 (1998).
   PubMed Web of Science ®Google Scholar
• Simons LA, Balasubramaniam S, Beins DM. Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis40, 299–308 (1981).
   PubMed Web of Science ®Google Scholar
• Zucker ML, Trowbridge C, Krehbiel P, Jackson B, Chernoff SB, Dujovne CA. Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy. Haemostasis16(1), 57–64 (1986).
   PubMedGoogle Scholar
• Bradlow BA, Chetty N, Birnbaum M, Baker SG, Seftel HC. Platelet function in familial hypercholesterolaemia in South Africa and the effects of probucol. Thromb. Res.26, 91–99 (1982).
   PubMed Web of Science ®Google Scholar
• Nomura S, Takahashi N, Inami N et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis174, 329–335 (2004).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’allier PL et al.; for the CART-2 Investigators. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis doi:10.1016/j.atherosclerosis.2006.11.039 (2007) (In press).
   PubMed Web of Science ®Google Scholar